v3.22.4
Financial Instruments and Fair Value Measures - Transfers of Assets or Liabilities Into or Out of Level 3 of the Fair Value Hierarchy (Details) - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Transfers of assets between the fair value measurement levels      
Transfers of assets into Level 3 of the fair value hierarchy $ 0    
Transfers of assets out of Level 3 of the fair value hierarchy 0    
Transfers of liabilities between the fair value measurement levels      
Transfers of liabilities into Level 3 of the fair value hierarchy 0    
Transfers of liabilities out of Level 3 of the fair value hierarchy 0    
Reconciliation of the fair value measurements that use significant unobservable inputs (Level 3)      
Beginning balance 14,887,000,000 $ 12,997,000,000 $ 7,340,000,000
Additions $ 32,000,000 [1] $ 0 $ 225,000,000 [1]
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Other Nonoperating Income (Expense) Other Nonoperating Income (Expense) Other Nonoperating Income (Expense)
Change in fair value recognized in net earnings $ (2,761,000,000) $ (2,679,000,000) $ (5,753,000,000)
Payments (1,296,000,000) (789,000,000) (321,000,000)
Ending balance $ 16,384,000,000 $ 14,887,000,000 $ 12,997,000,000
[1] Additions during the year ended December 31, 2022, represent contingent consideration liabilities assumed in the DJS acquisition. Additions during the year ended December 31, 2020, represent contingent consideration liabilities assumed in the Allergan and Luminera acquisitions (see Note 5).